Background: The highly selective RET inhibitor selpercatinib showed high efficacy and favorable toxicity profile in treating patients with RET-altered thyroid cancer (TC). Erectile dysfunction (ED) is a common adverse event observed in patients with advanced cancers. This study aims to evaluate the occurrence of ED in TC patients treated with selpercatinib. Methods: In a multi-center retrospective cohort study, we investigated the prevalence of ED in 25 male patients treated with selpercatinib for advanced TC. The management of ED was also examined. Results: 18/25 (78.3%) patients presented ED after starting selpercatinib treatment. However, only 2/18 (11.1%) spontaneously reported ED, while 16/18 (88.9%) reported ED only after specific questioning. Ten patients started treatment with phosphodiesterase-5 inhibitors (PDE-5i) with a significant improvement of ED. Conclusions: In this study, we observed that ED was not infrequently reported among men treated with selpercatinib for RET-altered TC. We believe that clinicians should actively inquire about ED in such patients at it may be underreported but may be amenable to treatment.
Erectile dysfunction in patients treated with selpercatinib for RET altered thyroid cancer
Matrone, AntonioCo-primo
;Gambale, Carla;Prete, Alessandro;Elisei, Rossella
Ultimo
2024-01-01
Abstract
Background: The highly selective RET inhibitor selpercatinib showed high efficacy and favorable toxicity profile in treating patients with RET-altered thyroid cancer (TC). Erectile dysfunction (ED) is a common adverse event observed in patients with advanced cancers. This study aims to evaluate the occurrence of ED in TC patients treated with selpercatinib. Methods: In a multi-center retrospective cohort study, we investigated the prevalence of ED in 25 male patients treated with selpercatinib for advanced TC. The management of ED was also examined. Results: 18/25 (78.3%) patients presented ED after starting selpercatinib treatment. However, only 2/18 (11.1%) spontaneously reported ED, while 16/18 (88.9%) reported ED only after specific questioning. Ten patients started treatment with phosphodiesterase-5 inhibitors (PDE-5i) with a significant improvement of ED. Conclusions: In this study, we observed that ED was not infrequently reported among men treated with selpercatinib for RET-altered TC. We believe that clinicians should actively inquire about ED in such patients at it may be underreported but may be amenable to treatment.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
